Nuoshen Pharmaceutical (Shanghai) Co. Ltd. has disclosed new NLRP3 inflammasome inhibitors potentially useful for the treatment of neuroinflammation, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s, Parkinson’s and Huntington’s disease.